LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced on July 31, 2026, that its Venezuelan subsidiary, LATAMEDAI VE, has entered into an agreement with the Venezuelan Institute for Scientific Research (IVIC) to develop a digital platform module. This module is intended to support access to designated laboratory and scientific services, marking a strategic move to apply its technology to institutional and enterprise workflows.
The collaboration will focus on designing, developing, testing, and implementing a digital interface that allows authorized business and institutional users to request laboratory services, schedule appointments, monitor request status, access approved reports, and complete payment processes. The proposed module aims to create a centralized digital workflow for organizations in sectors such as healthcare, pharmaceuticals, food production, agriculture, and related industries. The specific services will be determined by IVIC, adhering to technical, operational, security, and legal requirements set by both parties.
LataMed AI will begin working with IVIC to define functional requirements, user-access procedures, data architecture, payment workflows, and document-management capabilities. The parties will also establish protocols for handling, transmitting, storing, and accessing laboratory-related information. The platform's functionality may include electronic service requests, appointment scheduling, request-status tracking, secure payment facilitation, and controlled access to laboratory reports. However, the final functionality and implementation schedule remain subject to further development and approval.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "This agreement represents an opportunity to apply our technology to an important area of scientific and enterprise service delivery. Our objective is to work with IVIC to develop a responsible digital framework that makes it easier for authorized users to request services, manage appointments, monitor processes, and access approved information through a centralized platform."
Management believes this initiative could expand LataMed AI's capabilities beyond patient-facing telemedicine, demonstrating its technology's versatility in supporting institutional workflows involving healthcare, scientific services, and digital documentation. The move aligns with the company's broader strategy of building digital infrastructure that connects patients, healthcare professionals, pharmacies, insurers, payment providers, and other ecosystem participants.
If successful, the module could potentially be adapted for other institutional and enterprise environments in Venezuela and Latin America. However, any expansion would depend on separate agreements, technical readiness, regulatory approvals, and institutional needs. The agreement establishes the framework for development and evaluation but does not guarantee a specific implementation date, user adoption, revenue, or profitability.
For more information, visit LataMed AI's website or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
